ERCC1多态性与肺癌铂类化疗耐药的关系研究  

Correlation of excision repair cross-complementing gene1 polymorphisms and platinum chemotherapy resistance of lung cancer

作　　者：李代蓉[1] 杨燕青[2] 黄新华[2] 

机构地区：[1]重庆市肿瘤研究所肿瘤内科,重庆400030 [2]生物芯片上海国家工程研究中心,上海201203

出　　处：《现代生物医学进展》2011年第3期519-522,共4页Progress in Modern Biomedicine

基　　金：重庆市卫生局科研基金(编号07-2-180)

摘　　要：目的:研究DNA切除修复交叉互补基因1(excision repair cross-complementing gene1,ERCC1)单核苷酸多态性与非小细胞肺癌铂类药物化疗敏感性的关系。方法:应用基因测序方法检测89例以铂类药物为主要化疗方案的非小细胞肺癌患者的ERCC1 Asn118Asn基因型,,比较不同基因型与化疗疗效的关系。结果:89例患者化疗总有效率为29.2%。携带ERCC1 CC基因型、含至少一个变异基因型(TC和TT基因型)患者的有效率分别为38.5%和61.5%(X2=2.151,p=0.142),基因型在化疗有效组和无效组之间的分布无差异(p>0.05)。结论:ERCC1Asn118Asn单核苷酸多态性可能与非小细胞肺癌对铂类药物化疗的敏感性无关。Objective：To investigate the relationship between ERCC1 single nucleotide polymorphisms and sensitivity to Plat-inum-based chemotherapy among patients with advanced non small cell lung cancer.Methods：We used gene sequencing analysis to de-termine the single nucleotide polymorphisms（SNPs） i of excision repair cross-complementing gene1（ERCC1）in DNA from peripheral lymphocytes.Totally 89 patients with NSCLC were treated with Platinum-based chemotherapy,and clinical response was evaluated after 2 cycles.The association between ERCC1 gene polymorphisms and chemosensitivity were analyzed.Results：The overall response rate was 29.2.The verall response rate of ERCC1 CC genotypes and TT/CT genotypes were 38.5% and 61.5%（X2=2.151,p=0.142）.Chemother-apy response did not show statistically significant differences between the wild genotypes and the variant genotypes for the ERCC1 gene（38.5%vs61.5%,X2=2.151,p=0.142）.Conclusion：ERCC1 Asn118Asn SNP may be not associated with sensitivity to plat-inum-based chemotherapy in NSCLC patients.

关 键 词：DNA切除修复交叉互补基因1 非小细胞肺癌 化疗 药物敏感性 

分 类 号：R730.43[医药卫生—肿瘤] R734.2[医药卫生—临床医学]